C4 Therapeutics, Inc. (CCCC) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$26.13M*; Operating income -$26.42M; Depreciation and amortization $292.00K*.
- 2026-03-31: Basis Reported; EBITDA -$27.38M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$33.95M*; Operating income -$34.41M; Depreciation and amortization $460.00K*.
- 2025-06-30: Basis Reported; EBITDA -$27.89M*; Operating income -$28.50M; Depreciation and amortization $615.00K*.
Complete source-backed ebitda history.
- Available history
- 2024-03-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$26.13M* | -$26.42M | $292.00K* | $6.64M | -393.48%* | $37.00K* | -$1.57M* | (m) | $24.47M | (m) | $0.00 |
|---|
| 2026-03-31 | Reported | -$27.38M | (m) | (m) | (m) | -445.07% | $64.00K | -$29.94M | (m) | $24.61M | (m) | $0.00 |
|---|
| 2025-09-30 | Reported | -$33.95M* | -$34.41M | $460.00K* | $11.23M | -302.33%* | $411.00K* | -$31.21M* | (m) | $25.99M | (m) | $0.00 |
|---|
| 2025-06-30 | Reported | -$27.89M* | -$28.50M | $615.00K* | $6.46M | -431.47%* | $185.00K* | -$12.06M* | (m) | $26.20M | (m) | $0.00 |
|---|
| 2025-03-31 | Reported | -$28.71M | (m) | (m) | (m) | -396.63% | $0.00 | -$33.28M | (m) | $27.07M | (m) | $0.00 |
|---|
| 2024-09-30 | Reported | -$27.80M* | -$28.24M | $442.00K* | $15.36M | -180.98%* | -$13.00K* | -$24.13M* | (m) | $31.84M | (m) | $0.00 |
|---|
| 2024-06-30 | Reported | -$20.99M* | -$21.44M | $448.00K* | $12.01M | -174.86%* | $197.00K* | -$4.97M* | (m) | $23.75M | (m) | $0.00 |
|---|
| 2024-03-31 | Reported | -$31.77M | (m) | (m) | (m) | -1045.44% | $0.00 | -$18.12M | (m) | $22.53M | (m) | $0.00 |
|---|
| 2023-09-30 | Reported | -$27.36M* | -$27.81M | $447.00K* | $11.07M | -247.12%* | $600.00K* | -$30.71M* | (m) | $28.35M | (m) | $1.00M |
|---|
| 2023-06-30 | Reported | (m) | -$37.57M | (m) | $2.66M | (m) | $362.00K* | -$19.00M* | (m) | $29.93M | (m) | $0.00 |
|---|
| 2023-03-31 | Reported | (m) | -$36.23M | (m) | $3.76M | (m) | $589.00K | -$33.13M | (m) | $29.04M | (m) | $0.00 |
|---|
| 2022-09-30 | Reported | (m) | -$32.49M | (m) | $6.75M | (m) | $3.31M* | -$28.02M* | (m) | $29.66M | (m) | $0.00 |
|---|
| 2022-06-30 | Reported | (m) | -$27.38M | (m) | $13.83M | (m) | $529.00K* | -$22.20M* | (m) | $31.32M | (m) | $0.00* |
|---|
| 2022-03-31 | Reported | (m) | -$31.37M | (m) | $7.65M | (m) | $172.00K | -$26.60M | (m) | $26.20M | (m) | $0.00 |
|---|
| 2021-09-30 | Reported | (m) | -$24.25M | (m) | $8.50M | (m) | $0.00* | -$18.36M* | (m) | $24.30M | (m) | $0.00* |
|---|
| 2021-06-30 | Reported | (m) | -$22.12M | (m) | $9.78M | (m) | $747.00K* | -$18.00M* | (m) | $23.29M | (m) | $0.00* |
|---|
| 2021-03-31 | Reported | (m) | -$20.51M | (m) | (m) | (m) | $421.00K | -$24.93M | (m) | $20.53M | (m) | $0.00 |
|---|
| 2020-09-30 | Reported | (m) | -$18.35M | (m) | (m) | (m) | $284.00K* | -$14.40M* | (m) | $23.93M | (m) | -$167.00K |
|---|
| 2020-06-30 | Reported | (m) | -$10.86M | (m) | (m) | (m) | -$109.00K* | -$14.59M* | (m) | $17.76M | (m) | -$168.00K |
|---|
| 2020-03-31 | Reported | (m) | -$12.34M | (m) | (m) | (m) | $184.00K | -$16.67M | (m) | $16.31M | (m) | -$167.00K |
|---|
| 2019-09-30 | Reported | (m) | -$10.00M | (m) | (m) | (m) | (m) | (m) | (m) | $12.95M | (m) | $650.00K |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | (m) | -$115.22M | (m) | $35.95M | (m) | $607.00K | -$98.69M | (m) | $104.24M | (m) | $121.00K |
|---|
| 2024-12-31 | Reported | (m) | -$119.61M | (m) | $35.58M | (m) | $180.00K | -$65.16M | (m) | $110.64M | (m) | $131.00K |
|---|
| 2023-12-31 | Reported | (m) | -$139.03M | (m) | $20.76M | (m) | $1.71M | -$106.84M | (m) | $117.71M | (m) | $1.28M |
|---|
| 2022-12-31 | Reported | (m) | -$129.53M | (m) | $31.10M | (m) | $5.50M | -$105.94M | (m) | $117.84M | (m) | $0.00 |
|---|
| 2021-12-31 | Reported | (m) | -$82.13M | (m) | $45.78M | (m) | $1.28M | -$86.97M | (m) | $94.67M | (m) | $0.00 |
|---|
| 2020-12-31 | Reported | (m) | -$60.45M | (m) | (m) | (m) | $650.00K | -$67.25M | (m) | $78.44M | (m) | -$626.00K |
|---|
| 2019-12-31 | Reported | (m) | -$35.45M | (m) | (m) | (m) | $1.35M | $55.61M | (m) | $48.06M | (m) | $804.00K |
|---|